




COVID-19 Global and Regional Update

Patrick L. Osewe, Chief of Health Sector Group, ADB

13 May, 2020



The views expressed in this presentation are the views of the author/s and do not necessarily reflect the views or policies of the Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy of the data included in this presentation and accepts no responsibility for any consequence of their use. The countries listed in this presentation do not imply any view on ADB's part as to sovereignty or independent status or necessarily conform to ADB's terminology.


Global Situation Report

- Globally as of 11 May:
 - 4,177,502 confirmed cases
 - 286,330 deaths

Total Confirmed Cases by Country/Region



Total Confirmed Cases Worldwide



DMC Situation Report

- In DMCs as of 11 May:
 - 253,297 confirmed cases
 - 9,950 deaths

Total Confirmed Cases by Country/Region



Total Confirmed Cases Worldwide



COVID-19 Testing


- Two types of tests:

- PCR


- Determines current COVID-19 diagnosis
 - Requires highly trained workforce
 - Requires a laboratory
 - Cold chain for transport
 - Highly accurate when done by a trained HCW

- Serology


- Can detect antigens (for current COVID-19 diagnosis) or antibodies (for previous exposure to COVID-19) depending on the test
 - Very quick and can take a few minutes
 - Does not require a laboratory
 - Can be done by lay people
 - Does not require cold chain for transport
 - Not yet accurate (false positives and false negatives)




VS



Tests Conducted per 1 Million Population




Testing in DMCs Over Time



Lessons from Previous Pandemics

- The Spanish Influenza Pandemic had multiple waves of infection
- Countries must remain vigilant to mitigate subsequent outbreaks



The second wave of the 1918 pandemic was 5 times deadlier than the initial outbreak


Lessons from Previous Pandemics

- Pandemic Influenza (1918-1919)
 - Pandemic Influenza (1957-58)
 - H1N1 influenza pandemic (2009-2010)
 - SARS (2003-2004)
 - MERS (2012, 2014, 2015)
 - COVID-19 (2019- ongoing)
 - Ebola (2014-2016, 2018)
 - Zika (2015-2016)
-
- The diagram uses brackets to group the list items into three categories:
- Multiple waves** (red text): Includes Pandemic Influenza (1918-1919), Pandemic Influenza (1957-58), and H1N1 influenza pandemic (2009-2010).
 - Coronavirus family** (blue text): Includes SARS (2003-2004), MERS (2012, 2014, 2015), and COVID-19 (2019- ongoing).
 - Recent outbreaks** (black text): Includes Ebola (2014-2016, 2018) and Zika (2015-2016).

Treatment Options- FDA

- There are no drugs or other therapeutics presently approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19.
- Potential antiviral drugs under investigation (non-specific drugs)
 - Provisional use of **remdesivir** in severe cases
- Potential immune-based therapy under investigation
 - No evidence for or against use of **COVID-19 convalescent plasma** or **SARS-CoV-2 immune globulins** (injection of antibodies)

Vaccines- How long will it take?



Typical




Goal

“We’re thinking completely outside of what is, quote-unquote, normal,” said Kathrin Jansen, head of vaccine research and development for Pfizer. “We come up with unique approaches, we’re getting into contract negotiations with suppliers, and we haven’t seen a single clinical data point. It’s unheard of.”

How to Reopen?

- In order to reopen, several conditions must be met:
 - Testing capacity must be at scale
 - Real-time contact tracing, isolation of cases and quarantine of contacts must be enforced
 - Targeted control measures should be deployed in the event of an outbreak
 - Data driven decision making is critical
 - Travel –ongoing discussions



Imperial College of London predicts a cycle of “triggers” under which suppression measures are instituted and relaxed